Evidence map›Paper›PMID 36031045›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2022

Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation.

Monica Josiane Rodrigues-Jesus, Marianna Teixeira de Pinho Favaro, Aléxia Adrianne Venceslau-Carvalho, Maria Fernanda de Castro-Amarante, Bianca da Silva Almeida, Mariângela de Oliveira Silva, Robert Andreata-Santos, Cecilia Gomes Barbosa, Samantha Carvalho Maia Brito, Lucio H Freitas-Junior and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Monica Josiane Rodrigues-JesusLaboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil; Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, VA, USA.
Marianna Teixeira de Pinho FavaroLaboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil; Scientific Platform Pasteur/USP, University of São Paulo, São Paulo, Brazil.
Aléxia Adrianne Venceslau-CarvalhoLaboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil; Scientific Platform Pasteur/USP, University of São Paulo, São Paulo, Brazil.
Maria Fernanda de Castro-AmaranteLaboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil; Scientific Platform Pasteur/USP, University of São Paulo, São Paulo, Brazil.
Bianca da Silva AlmeidaLaboratory of Antigen Targeting for Dendritic Cells, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Mariângela de Oliveira SilvaLaboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil; Scientific Platform Pasteur/USP, University of São Paulo, São Paulo, Brazil; Laboratory of Antigen Targeting for Dendritic Cells, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Robert Andreata-SantosRetrovirology Laboratory, Immunology and Microbiology Department, Federal University of São Paulo, São Paulo, Brazil.
Cecilia Gomes BarbosaPhenotypic Screening Platform of the Institute of Biomedical Sciences of the University of São Paulo, São Paulo, Brazil.
Samantha Carvalho Maia BritoLaboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Lucio H Freitas-JuniorPhenotypic Screening Platform of the Institute of Biomedical Sciences of the University of São Paulo, São Paulo, Brazil.
Silvia Beatriz BoscardinLaboratory of Antigen Targeting for Dendritic Cells, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Luís Carlos de Souza FerreiraLaboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil; Scientific Platform Pasteur/USP, University of São Paulo, São Paulo, Brazil. Electronic address: lcsf@usp.br.
Universidade de São Paulo · BRUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of safe and effective vaccine formulations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a hallmark in the history of vaccines. Here we report a COVID-19 subunit vaccine based on a SARS-CoV-2 Spike protein receptor binding domain (RBD) incorporated into nano-multilamellar vesicles (NMV) associated with monophosphoryl lipid A (MPLA). The results based on immunization of C57BL/6 mice demonstrated that recombinant antigen incorporation into NMVs improved antibody and T-cell responses without inducing toxic effects under both in vitro and in vivo conditions. Administration of RBD-NMV-MPLA formulations modulated antigen avidity and IgG subclass responses, whereas MPLA incorporation improved the activation of CD4

Indexed as

COVID-19SARS-CoV-2AnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansImmunityImmunoglobulin GLipidsMiceMice, Inbred BALB CMice, Inbred C57BLSpike Glycoprotein, CoronavirusVaccines, SubunitAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GLipidsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, SubunitLipid-based nanoparticlesNano-multilamellar vesiclesRBDSARS-CoV-2Vaccine

Identifiers

PMID36031045
PMCPMC9420030
OpenAlexW4293796754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.